awmsg logo



icatibant acetate (Firazyr®)


Reference No. 3293


Appraisal information

icatibant acetate (Firazyr®) 30 mg solution for injection


Company: Shire Orphan Therapies GmbH
BNF category: Respiratory system
NMG meeting date: 11/04/2018
AWMSG meeting date: 23/05/2018
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Symptomatic treatment of acute attacks of hereditary angioedema in adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download